Actively Recruiting

Phase 2
Age: 18Years - 70Years
All Genders
NCT06655896

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

Led by Novartis Pharmaceuticals · Updated on 2026-05-13

96

Participants Needed

87

Research Sites

408 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.

CONDITIONS

Official Title

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participant must meet 2013 classification criteria for systemic sclerosis and have diffuse cutaneous systemic sclerosis
  • Disease onset from first non-Raynaud symptoms within 7 years before screening
  • Severe, progressive systemic sclerosis defined by at least one of: interstitial lung disease, severe skin disease, or significant cardiac involvement
  • Received all recommended vaccinations for immunocompromised patients
Not Eligible

You will not qualify if you...

  • Conditions preventing medication washout or eligibility for anti-CD19 CAR-T therapy
  • History of hypersensitivity to ingredients in rapcabtagene autoleucel or rituximab
  • Rituximab treatment deemed inappropriate by investigator
  • Medical conditions unrelated to systemic sclerosis that limit ability to tolerate lymphodepletion and CAR-T therapy
  • Other rheumatic diseases besides diffuse cutaneous systemic sclerosis, except secondary Sjogren's syndrome or scleroderma myopathy
  • Pre-existing pulmonary hypertension
  • Significant kidney disease at screening
  • Uncontrolled stage II hypertension at screening
  • Vaccination with live attenuated vaccines within 6 weeks before randomization

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 87 locations

1

UCLA

Los Angeles, California, United States, 90095

Actively Recruiting

2

UCSF

San Francisco, California, United States, 94115

Actively Recruiting

3

UCSF

San Francisco, California, United States, 94115

Actively Recruiting

4

Sutter Health Network

San Pablo, California, United States, 94806

Actively Recruiting

5

FL Medical Clinic Orlando Health

Zephyrhills, Florida, United States, 33542

Actively Recruiting

6

Northwestern University

Chicago, Illinois, United States, 60611

Actively Recruiting

7

University Of Iowa

Iowa City, Iowa, United States, 52242

Actively Recruiting

8

Boston Medical Center

Boston, Massachusetts, United States, 02118

Actively Recruiting

9

Michigan Med University of Michigan

Ann Arbor, Michigan, United States, 48109 5271

Actively Recruiting

10

University of Minnesota

Minneapolis, Minnesota, United States, 55455

Actively Recruiting

11

James Cancer Hospital

Columbus, Ohio, United States, 43210

Actively Recruiting

12

Oregon Health Sciences University

Portland, Oregon, United States, 97239

Actively Recruiting

13

Avera Cancer

Sioux Falls, South Dakota, United States, 57105

Actively Recruiting

14

LDS Hospital

Salt Lake City, Utah, United States, 84143

Actively Recruiting

15

Novartis Investigative Site

Camperdown, New South Wales, Australia, 2050

Actively Recruiting

16

Novartis Investigative Site

Darlinghurst, New South Wales, Australia, 2010

Actively Recruiting

17

Novartis Investigative Site

Graz, Austria, 8036

Actively Recruiting

18

Novartis Investigative Site

Vienna, Austria, 1090

Actively Recruiting

19

Novartis Investigative Site

Ghent, Belgium, 9000

Actively Recruiting

20

Novartis Investigative Site

Salvador, Estado de Bahia, Brazil, 41253-190

Actively Recruiting

21

Novartis Investigative Site

Barretos, São Paulo, Brazil, 14784 400

Actively Recruiting

22

Novartis Investigative Site

São Paulo, São Paulo, Brazil, 01232-010

Actively Recruiting

23

Novartis Investigative Site

São Paulo, São Paulo, Brazil, 01308-050

Actively Recruiting

24

Novartis Investigative Site

Olomouc, Czechia, 779 00

Actively Recruiting

25

Novartis Investigative Site

Prague, Czechia, 128 00

Actively Recruiting

26

Novartis Investigative Site

Aarhus N, Denmark, 8200

Actively Recruiting

27

Novartis Investigative Site

Bordeaux, France, 33076

Actively Recruiting

28

Novartis Investigative Site

Dijon, France, 21000

Actively Recruiting

29

Novartis Investigative Site

Lille, France, 59037

Actively Recruiting

30

Novartis Investigative Site

Lyon, France, 69003

Actively Recruiting

31

Novartis Investigative Site

Montpellier, France, 34295

Actively Recruiting

32

Novartis Investigative Site

Paris, France, 75014

Actively Recruiting

33

Novartis Investigative Site

Rennes, France, 35033

Actively Recruiting

34

Novartis Investigative Site

Freiburg im Breisgau, Baden-Wurttemberg, Germany, 79106

Actively Recruiting

35

Novartis Investigative Site

Göttingen, Lower Saxony, Germany, 37075

Actively Recruiting

36

Novartis Investigative Site

Leipzig, Saxony, Germany, 04103

Actively Recruiting

37

Novartis Investigative Site

Halle, Saxony-Anhalt, Germany, 06120

Actively Recruiting

38

Novartis Investigative Site

Jena, Thuringia, Germany, 07740

Actively Recruiting

39

Novartis Investigative Site

Berlin, Germany, 13353

Actively Recruiting

40

Novartis Investigative Site

Lübeck, Germany, 23538

Actively Recruiting

41

Novartis Investigative Site

Mainz, Germany, 55131

Actively Recruiting

42

Novartis Investigative Site

Nuremberg, Germany, 90419

Actively Recruiting

43

Novartis Investigative Site

Ulm, Germany, 89081

Actively Recruiting

44

Novartis Investigative Site

Debrecen, Hajdu Bihar Megye, Hungary, 4032

Actively Recruiting

45

Novartis Investigative Site

Budapest, Hungary, H-1083

Actively Recruiting

46

Novartis Investigative Site

Haifa, Israel, 3109601

Actively Recruiting

47

Novartis Investigative Site

Ramat Gan, Israel, 5265601

Actively Recruiting

48

Novartis Investigative Site

Tel Aviv, Israel, 6423906

Actively Recruiting

49

Novartis Investigative Site

Ancona, AN, Italy, 60126

Actively Recruiting

50

Novartis Investigative Site

Bergamo, BG, Italy, 24127

Actively Recruiting

51

Novartis Investigative Site

Brescia, BS, Italy, 25123

Actively Recruiting

52

Novartis Investigative Site

Genova, GE, Italy, 16132

Actively Recruiting

53

Novartis Investigative Site

Milan, MI, Italy, 20122

Actively Recruiting

54

Novartis Investigative Site

Milan, MI, Italy, 20132

Actively Recruiting

55

Novartis Investigative Site

Pescara, PE, Italy, 65124

Actively Recruiting

56

Novartis Investigative Site

Perugia, PG, Italy, 06129

Actively Recruiting

57

Novartis Investigative Site

Pisa, PI, Italy, 56126

Actively Recruiting

58

Novartis Investigative Site

Pavia, PV, Italy, 27100

Actively Recruiting

59

Novartis Investigative Site

Roma, RM, Italy, 00168

Actively Recruiting

60

Novartis Investigative Site

Udine, UD, Italy, 33100

Actively Recruiting

61

Novartis Investigative Site

Sapporo, Hokkaido, Japan, 060-8648

Actively Recruiting

62

Novartis Investigative Site

Sendai, Miyagi, Japan, 9808574

Actively Recruiting

63

Novartis Investigative Site

Suita, Osaka, Japan, 565-0871

Actively Recruiting

64

Novartis Investigative Site

Bunkyo-ku, Tokyo, Japan, 113-8603

Actively Recruiting

65

Novartis Investigative Site

Fukuoka, Japan, 8128582

Actively Recruiting

66

Novartis Investigative Site

Ishikawa, Japan, 9208641

Actively Recruiting

67

Novartis Investigative Site

Kyoto, Japan, 6068507

Actively Recruiting

68

Novartis Investigative Site

Utrecht, Netherlands, 3584 CX

Actively Recruiting

69

Novartis Investigative Site

Singapore, Singapore, 169608

Actively Recruiting

70

Novartis Investigative Site

Seoul, South Korea, 04763

Actively Recruiting

71

Novartis Investigative Site

Seoul, South Korea, 06591

Actively Recruiting

72

Novartis Investigative Site

Santiago Compostela, A Coruna, Spain, 15706

Actively Recruiting

73

Novartis Investigative Site

Santander, Cantabria, Spain, 39008

Actively Recruiting

74

Novartis Investigative Site

Pamplona, Navarre, Spain, 31008

Actively Recruiting

75

Novartis Investigative Site

Barcelona, Spain, 08035

Actively Recruiting

76

Novartis Investigative Site

Barcelona, Spain, 08041

Actively Recruiting

77

Novartis Investigative Site

Córdoba, Spain, 14004

Actively Recruiting

78

Novartis Investigative Site

Madrid, Spain, 28009

Actively Recruiting

79

Novartis Investigative Site

Madrid, Spain, 28041

Actively Recruiting

80

Novartis Investigative Site

Málaga, Spain, 29010

Actively Recruiting

81

Novartis Investigative Site

Salamanca, Spain, 37007

Actively Recruiting

82

Novartis Investigative Site

Valencia, Spain, 46026

Actively Recruiting

83

Novartis Investigative Site

Geneva, Switzerland, 1211

Actively Recruiting

84

Novartis Investigative Site

Lausanne, Switzerland, 1011

Actively Recruiting

85

Novartis Investigative Site

Zurich, Switzerland, 8091

Actively Recruiting

86

Novartis Investigative Site

Taichung, Taiwan, 407219

Actively Recruiting

87

Novartis Investigative Site

Sheffield, South Yorkshire, United Kingdom, S10 2JF

Actively Recruiting

Loading map...

Research Team

N

Novartis Pharmaceuticals

CONTACT

N

Novartis Pharmaceuticals

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis | DecenTrialz